Last reviewed · How we verify
Reference Eutirox®
At a glance
| Generic name | Reference Eutirox® |
|---|---|
| Sponsor | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Dizziness
- Nasal congestion
- Elevated Alanine Aminotransferase
- Elevated Aspartate Aminotransferase
Key clinical trials
- A Study of Armour® Thyroid Compared to Synthetic T4 (Levothyroxine) in Previously Hypothyroid Participants (PHASE2)
- BE of Euthyrox® Tablets (Merck Nantong Versus Merck Darmstadt Sites) (PHASE1)
- A Comparative Study of New Formulation and Approved Formulation for Levothyroxine in Healthy Volunteers (PHASE1)
- Bioavailability and Safety of Two Oral Fixed Dose Preparations Containing 18 mg Ivermectin (IVM 18 MG TABLETS, LICONSA S.A., Spain) Versus Reference Dosing (Weight Based) Containing 6 mg Ivermectin (REVECTINA®, Abbott Laboratórios do Brasil Ltda, Brazil) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: